

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5463214

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT										
NATURE OF CONVEYANCE:	Corrective Assignment to correct the COVER SHEET (LAST NAME OF INVENTOR GAGETE MATEOS) previously recorded on Reel 048782 Frame 0441. Assignor(s) hereby confirms the ASSIGNMENT.										
CONVEYING PARTY DATA											
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>JULIO CASTRO</td><td>03/03/2019</td></tr><tr><td>ANDRÉS GAGETE MATEOS</td><td>03/03/2019</td></tr><tr><td>PETER J. MACHIN</td><td>03/13/2019</td></tr><tr><td>CHRISTOPHER LOREN VANDEUSEN</td><td>03/08/2019</td></tr></tbody></table>	Name	Execution Date	JULIO CASTRO	03/03/2019	ANDRÉS GAGETE MATEOS	03/03/2019	PETER J. MACHIN	03/13/2019	CHRISTOPHER LOREN VANDEUSEN	03/08/2019	
Name	Execution Date										
JULIO CASTRO	03/03/2019										
ANDRÉS GAGETE MATEOS	03/03/2019										
PETER J. MACHIN	03/13/2019										
CHRISTOPHER LOREN VANDEUSEN	03/08/2019										
RECEIVING PARTY DATA											
Name:	ARTAX BIOPHARMA INC.										
Street Address:	1 BROADWAY, 14TH FLOOR										
City:	CAMBRIDGE										
State/Country:	MASSACHUSETTS										
Postal Code:	02142										
PROPERTY NUMBERS Total: 1											
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>16287771</td></tr></tbody></table>	Property Type	Number	Application Number:	16287771							
Property Type	Number										
Application Number:	16287771										
CORRESPONDENCE DATA											
Fax Number:	(617)728-7100										
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>											
Phone:	(617) 728-8603										
Email:	BOSPatents@dechert.com										
Correspondent Name:	DECHERT LLP										
Address Line 1:	ONE INTERNATIONAL PLACE, 40TH FLOOR										
Address Line 2:	100 OLIVER STREET										
Address Line 4:	BOSTON, MASSACHUSETTS 02110-2605										
ATTORNEY DOCKET NUMBER:	397743-008US (165588)										
NAME OF SUBMITTER:	NICHOLAS PRAIRIE										
SIGNATURE:	/Nicholas Prairie/										
DATE SIGNED:	04/08/2019										
Total Attachments: 4											

source=2019-04-03 Artax (397743-008US) 165588 Corrective Assignment#page1.tif
source=2019-04-03 Artax (397743-008US) 165588 Corrective Assignment#page2.tif
source=2019-04-03 Artax (397743-008US) 165588 Corrective Assignment#page3.tif
source=2019-04-03 Artax (397743-008US) 165588 Corrective Assignment#page4.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5455922

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JULIO CASTRO	03/03/2019
ANDRÉS GAGETE MATEOS	03/03/2019
PETER J. MACHIN	03/13/2019
CHRISTOPHER LOREN VANDEUSEN	03/08/2019
RECEIVING PARTY DATA	
Name:	ARTAX BIOPHARMA INC.
Street Address:	1 BROADWAY, 14TH FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16287771
CORRESPONDENCE DATA	
Fax Number:	(617)728-7100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 728-8603
Email:	BOSPatents@dechert.com
Correspondent Name:	DECHERT LLP
Address Line 1:	ONE INTERNATIONAL PLACE, 40TH FLOOR
Address Line 2:	100 OLIVER STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110-2605
ATTORNEY DOCKET NUMBER:	397743-008US (165588)
NAME OF SUBMITTER:	NICHOLAS PRAIRIE
SIGNATURE:	/Nicholas Prairie/
DATE SIGNED:	04/03/2019
Total Attachments: 3	
source=Artax (165588) Combined declaration assignment#page1.tif	
source=Artax (165588) Combined declaration assignment#page2.tif	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

DECLARATION:

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT:

WHEREAS, we, the undersigned,

Julio CASTRO, resident of Ernest Lluch 32, Mataro, Barcelona, 08302, SPAIN;

Andrés GAGETE MATEOS, resident of Roger de Lloria 6, Pta 6, Valencia, 46002, SPAIN;

Peter J. MACHIN, resident of 31 Streatham Common North, Streatham, London, SW16 3HP, UNITED KINGDOM;

Christopher Loren VANDEUSEN, resident of 8 Benson Road, Hopkinton, Massachusetts 01748, USA;

are inventors of the invention described and claimed in "**CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION**" and hereby execute an application for a patent of the United States, having Application No. 16/287,771, filing date of February 27, 2019, and

are also aware of the following priority applications:

62/635,834, filing date of February 27, 2018;

WHEREAS, **ARTAX BIOPHARMA INC.** (hereinafter termed "Assignee"), having a place of business at 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142, USA, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.


2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.


ARTAX BIOPHARMA INC. ("Assignee")

By:  _____

Name: Damia Tormo


Title: CEO


Date: MARCH 2nd 2019


By: 
Julio CASTRO

Date: MARCH 3rd, 2019

WITNESSES:


Signature: 

Signature: 

By: 
Peter J. MACHIN

Date: 13. 03. 19

WITNESSES:

Signature: 


Signature: _____


By: 
Andrés GAGETE MATEOS

Date: MARCH 7th 2019

WITNESSES:


Signature: 

Signature: 

By: 
Christopher Loren VANDEUSEN

Date: March 8, 2019

WITNESSES:

Signature: 

Signature: _____